세계의 창상 치료용 생물학적 제제 시장 규모 조사 : 제품별, 창상 유형별, 최종사용자별, 지역별 예측(2022-2032년)

Global Wound Care Biologics Market is valued at approximately USD 2.09 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 11% over the forecast period 2024-2032. Wound Care Biologics encompasses the utilization of biological products derived from living organisms to expedite wound healing. This category includes growth factors, skin substitutes, and tissue-engineered materials designed to emulate natural healing processes. These products are instrumental in the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores, where conventional treatments often fall short. By promoting cell proliferation, collagen synthesis, and angiogenesis, wound care biologics enhance tissue regeneration and significantly reduce healing times. They are vital in improving patient outcomes, particularly in cases with compromised healing capacities, by offering an advanced, targeted approach to wound management.

The burgeoning incidence of chronic wounds is a major driver for the wound care biologics market. The global aging population, coupled with the rising prevalence of diabetes and obesity, results in a growing number of patients with chronic wounds necessitating advanced treatment solutions. Products like skin substitutes and growth factors are becoming increasingly essential in accelerating the healing process for these conditions. Technological advancements in biotechnology have paved the way for innovative wound care biologics that are more effective and efficient. The development of bioengineered skin substitutes and tissue-engineered products that mimic natural healing processes not only promotes faster healing but also reduces infection risks, garnering significant traction among healthcare providers. Furthermore, increasing awareness and adoption of biologics in wound care among healthcare professionals and patients contribute to market growth, driven by educational initiatives and training programs for healthcare providers. However, the high cost of wound care biologics and reimbursement challenges are significant barriers to market growth. Stringent reimbursement policies in many healthcare systems can limit the adoption of costly biologic treatments. Additionally, the financial burden on patients can hinder widespread use, especially in regions with limited healthcare coverage. Nevertheless, emerging markets in Asia-Pacific, Latin America, and Africa present substantial growth opportunities due to rising healthcare expenditure and improving healthcare infrastructure. These regions are experiencing increased demand for advanced wound care solutions driven by growing healthcare awareness and access. Collaborations and partnerships among biotechnology companies, research institutions, and healthcare providers also foster innovation in wound care biologics, leading to the creation of new products and market expansion.

North America is expected to dominate the wound care biologics market during the forecast period, attributed to the growing diabetic population and increasing cases of burn injuries. The region's prevalence of lifestyle disorders leading to chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers is anticipated to drive market growth. Meanwhile, the Asia Pacific market is projected to grow at the fastest rate over the forecast period, owing to significant advancements in healthcare infrastructure and increasing awareness of advanced wound care solutions.

Major market players included in this report are:

• Smith & Nephew (UK)
• Molnlycke Health Care AB (Sweden)
• Integra LifeSciences Corporation (US)
• Wright Medical (US)
• MiMedx Group (US)
• Vericel Corporation (US)
• Anika Therapeutics (US)
• Osiris Therapeutics (US)
• Organogenesis (US)
• Kerecis (Iceland)

The detailed segments and sub-segment of the market are explained below:

By Product:

• Biologic Skin Substitutes
• Topical Agents

By Wound Type:

• Ulcers
• Surgical & Traumatic Wounds
• Burns

By End User:

• Hospitals
• Ambulatory Surgical Centers
• Burn Centers & Wound Clinics

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Wound Care Biologics Market Executive Summary

• 1.1. Global Wound Care Biologics Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Product
  • 1.3.2. By Wound Type
  • 1.3.3. By End User
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Wound Care Biologics Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Wound Care Biologics Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Increasing Incidence of Chronic Wounds
  • 3.1.2. Advancements in Biotechnology
  • 3.1.3. Growing Awareness and Adoption
• 3.2. Market Challenges
  • 3.2.1. High Costs and Reimbursement Issues
• 3.3. Market Opportunities
  • 3.3.1. Emerging Markets
  • 3.3.2. Collaborations and Partnerships

Chapter 4. Global Wound Care Biologics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Wound Care Biologics Market Size & Forecasts by Product 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Wound Care Biologics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Biologic Skin Substitutes
  • 5.2.2. Topical Agents

Chapter 6. Global Wound Care Biologics Market Size & Forecasts by Wound Type 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Wound Care Biologics Market: Wound Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Ulcers
  • 6.2.2. Surgical & Traumatic Wounds
  • 6.2.3. Burns

Chapter 7. Global Wound Care Biologics Market Size & Forecasts by End User 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Wound Care Biologics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Hospitals
  • 7.2.2. Ambulatory Surgical Centers
  • 7.2.3. Burn Centers & Wound Clinics

Chapter 8. Global Wound Care Biologics Market Size & Forecasts by Region 2022-2032

• 8.1. North America Wound Care Biologics Market
  • 8.1.1. U.S. Wound Care Biologics Market
    • 8.1.1.1. Product breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Wound Type breakdown size & forecasts, 2022-2032
    • 8.1.1.3. End User breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Wound Care Biologics Market
• 8.2. Europe Wound Care Biologics Market
  • 8.2.1. U.K. Wound Care Biologics Market
  • 8.2.2. Germany Wound Care Biologics Market
  • 8.2.3. France Wound Care Biologics Market
  • 8.2.4. Spain Wound Care Biologics Market
  • 8.2.5. Italy Wound Care Biologics Market
  • 8.2.6. Rest of Europe Wound Care Biologics Market
• 8.3. Asia-Pacific Wound Care Biologics Market
  • 8.3.1. China Wound Care Biologics Market
  • 8.3.2. India Wound Care Biologics Market
  • 8.3.3. Japan Wound Care Biologics Market
  • 8.3.4. Australia Wound Care Biologics Market
  • 8.3.5. South Korea Wound Care Biologics Market
  • 8.3.6. Rest of Asia Pacific Wound Care Biologics Market
• 8.4. Latin America Wound Care Biologics Market
  • 8.4.1. Brazil Wound Care Biologics Market
  • 8.4.2. Mexico Wound Care Biologics Market
  • 8.4.3. Rest of Latin America Wound Care Biologics Market
• 8.5. Middle East & Africa Wound Care Biologics Market
  • 8.5.1. Saudi Arabia Wound Care Biologics Market
  • 8.5.2. South Africa Wound Care Biologics Market
  • 8.5.3. Rest of Middle East & Africa Wound Care Biologics Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Smith & Nephew (UK)
  • 9.1.2. Molnlycke Health Care AB (Sweden)
  • 9.1.3. Integra LifeSciences Corporation (US)
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Smith & Nephew (UK)
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Molnlycke Health Care AB (Sweden)
  • 9.3.3. Integra LifeSciences Corporation (US)
  • 9.3.4. Wright Medical (US)
  • 9.3.5. MiMedx Group (US)
  • 9.3.6. Vericel Corporation (US)
  • 9.3.7. Anika Therapeutics (US)
  • 9.3.8. Osiris Therapeutics (US)
  • 9.3.9. Organogenesis (US)
  • 9.3.10. Kerecis (Iceland)
  • 9.3.11. Solsys Medical (US)
  • 9.3.12. ACell (US)
  • 9.3.13. Lavior Inc. (US)
  • 9.3.14. Marine Polymer Technologies, Inc. (US)

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes